Live Breaking News & Updates on A Equecabtagene Autoleucel

Stay updated with breaking news from A equecabtagene autoleucel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

/PRNewswire/ IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody. ....

Lugui Qiu , Adimab Incyte , Chunrui Li , Eli Lilly , A Equecabtagene Autoleucel , Equecabtagene Autoleucel , Innovent Biologics , Innovent Biologics Inc , International Myeloma Society , Huazhong University Of Science Technology , Chinese Academy Of Medical Science Hematology Hospital , Md Anderson Cancer Center , Tongji Medical College , China National Medical Products Administration , Complete Response , Abstract Code , Myeloma Society , Annual Meeting , Refractory Multiple , Chinese Academy , Medical Science Hematology Hospital , Tongji Hospital , Huazhong University , New Drug Application , National Medical Products Administration , Sintilimab Injection ,

IASO Bio Announces CT103A Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations by the FDA

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative. ....

Equecabtagene Autoleucel , A Equecabtagene Autoleucel , China National Medical Products Administration , Drug Administration , Innovent Biologics Inc , Regenerative Medicine Advanced Therapy , Fast Track , New Drug Application , Breakthrough Therapy Designation , Orphan Drug Designation , Neuromyelitis Optica Spectrum Disorder , Innovent Biologics , Century Cures Act , Accelerated Approval , Priority Review , National Medical Products Administration , Iaso Biotherapeutics ,